{"success":true,"data":{"pressRelease":{"id":"167360","rtpr_id":"nGNX6s37Y4-20261013","ticker":"BWAY","exchange":"","all_tickers":["BWAY"],"title":"BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives","author":"Globe Newswire","published_at":"2026-10-13T11:30:00.873Z","article_body":"BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay\nLtd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global\nleader in advanced noninvasive brain stimulation technologies, today announced\nfurther expansion in the number of medical policies across the U.S. providing\nfavorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.\n\nWith this update, there are now over 70 million covered lives in the U.S. with\naccess to policies covering SWIFT. The announcement comes amid continued\nmomentum in favorable policy changes for Deep TMS generally, including for the\ntreatment major depressive disorder (MDD) and obsessive-compulsive disorder\n(OCD) patients.\n\n\"This announcement highlights the increasing pathways toward SWIFT adoption,\"\nsaid Hadar Levy, Chief Executive Officer of BrainsWay. “Our progress in this\narea is enabled by the strong and increasing body of data demonstrating high\nefficacy and durability of our accelerated SWIFT protocol for depression, as\nwell as the impressive body of publications supporting the use of Deep TMS\nacross our multiple FDA-cleared indications. We continue our painstaking\nefforts on educating stakeholders everywhere as to the benefits of Deep TMS,\nwith the ultimate goal of advancing access to patient care through increased\ncoverage of innovative interventional psychiatry therapies,\" concluded Mr.\nLevy.\n\nBrainsWay continues to lead the field with its proprietary H-coil technology,\nrobust clinical research, and ongoing collaboration with leaders in the mental\nhealth space to increase awareness and improve the lives of patients.\n\nAbout BrainsWay\nBrainsWay is a global leader in advanced noninvasive neurostimulation\ntreatments for mental health disorders. The Company is boldly advancing\nneuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep\nTMS™) platform technology to improve health and transform lives. BrainsWay\nis the first and only TMS company to obtain three FDA-cleared indications\nbacked by pivotal clinical studies demonstrating clinically proven efficacy.\nCurrent indications include major depressive disorder (including reduction of\nanxiety symptoms, commonly referred to as anxious depression),\nobsessive-compulsive disorder, and smoking addiction. The Company is dedicated\nto leading through superior science and building on its unparalleled body of\nclinical evidence. Additional clinical trials of Deep TMS in various\npsychiatric, neurological, and addiction disorders are underway. Founded in\n2003, with operations in the United States and Israel, BrainsWay is committed\nto increasing global awareness of and broad access to Deep TMS. For the latest\nnews and information about BrainsWay, please visit www.brainsway.com.\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995. Such\nstatements may be preceded by the words “intends,” “may,” “will,”\n“plans,” “expects,” “anticipates,” “projects,” “predicts,”\n“estimates,” “aims,” “believes,” “hopes,” “potential” or\nsimilar words, and also includes any financial guidance and projections\ncontained herein. These forward-looking statements and their implications are\nbased on the current expectations of the management of the Company only and\nare subject to a number of factors and uncertainties that could cause actual\nresults to differ materially from those described in the forward-looking\nstatements. In addition, historical results or conclusions from scientific\nresearch and clinical studies do not guarantee that future results would\nsuggest similar conclusions or that historical results referred to herein\nwould be interpreted similarly in light of additional research or otherwise.\nThe following factors, among others, could cause actual results to differ\nmaterially from those described in the forward-looking statements: risks\nrelating to the Company’s ability to consummate, finance and close proposed\nor potential investments, inadequacy of financial resources to meet future\ncapital requirements; changes in technology and market requirements; delays or\nobstacles in launching and/or successfully completing planned studies and\nclinical trials; failure to obtain approvals by regulatory agencies on the\nCompany’s anticipated timeframe, or at all; inability to retain or attract\nkey employees whose knowledge is essential to the development of Deep TMS\nproducts; unforeseen difficulties with Deep TMS products and processes, and/or\ninability to develop necessary enhancements; unexpected costs related to Deep\nTMS products; failure to obtain and maintain adequate protection of the\nCompany’s intellectual property, including intellectual property licensed to\nthe Company; the potential for product liability; changes in legislation and\napplicable rules and regulations; unfavorable market perception and acceptance\nof Deep TMS technology; inadequate or delays in reimbursement from third-party\npayers, including insurance companies and Medicare; inability to commercialize\nDeep TMS, including internationally, by the Company or through third-party\ndistributors; product development by competitors; inability to timely develop\nand introduce new technologies, products and applications, which could cause\nthe actual results or performance of the Company to differ materially from\nthose contemplated in such forward-looking statements.\n\nAny forward-looking statement in this press release speaks only as of the date\nof this press release. The Company undertakes no obligation to publicly update\nor review any forward-looking statement, whether as a result of new\ninformation, future developments or otherwise, except as may be required by\nany applicable securities laws. More detailed information about the risks and\nuncertainties affecting the Company is contained under the heading “Risk\nFactors” in the Company’s filings with the U.S. Securities and Exchange\nCommission.\n\nContacts: \nBrainsWay:\nIdo Marom\nChief Financial Officer\nIdo.Marom@BrainsWay.com\n\nInvestors:\nBrian Ritchie\nLifeSci Advisors LLC\nbritchie@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ea01c8f7-39be-46d2-a8e0-bc05994f170e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6s37Y4-20261013","title":"BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives","author":"Globe Newswire","ticker":"BWAY","created":"2026-10-13T11:30:00.873Z","tickers":["BWAY"],"exchange":"","article_body":"BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay\nLtd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global\nleader in advanced noninvasive brain stimulation technologies, today announced\nfurther expansion in the number of medical policies across the U.S. providing\nfavorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.\n\nWith this update, there are now over 70 million covered lives in the U.S. with\naccess to policies covering SWIFT. The announcement comes amid continued\nmomentum in favorable policy changes for Deep TMS generally, including for the\ntreatment major depressive disorder (MDD) and obsessive-compulsive disorder\n(OCD) patients.\n\n\"This announcement highlights the increasing pathways toward SWIFT adoption,\"\nsaid Hadar Levy, Chief Executive Officer of BrainsWay. “Our progress in this\narea is enabled by the strong and increasing body of data demonstrating high\nefficacy and durability of our accelerated SWIFT protocol for depression, as\nwell as the impressive body of publications supporting the use of Deep TMS\nacross our multiple FDA-cleared indications. We continue our painstaking\nefforts on educating stakeholders everywhere as to the benefits of Deep TMS,\nwith the ultimate goal of advancing access to patient care through increased\ncoverage of innovative interventional psychiatry therapies,\" concluded Mr.\nLevy.\n\nBrainsWay continues to lead the field with its proprietary H-coil technology,\nrobust clinical research, and ongoing collaboration with leaders in the mental\nhealth space to increase awareness and improve the lives of patients.\n\nAbout BrainsWay\nBrainsWay is a global leader in advanced noninvasive neurostimulation\ntreatments for mental health disorders. The Company is boldly advancing\nneuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep\nTMS™) platform technology to improve health and transform lives. BrainsWay\nis the first and only TMS company to obtain three FDA-cleared indications\nbacked by pivotal clinical studies demonstrating clinically proven efficacy.\nCurrent indications include major depressive disorder (including reduction of\nanxiety symptoms, commonly referred to as anxious depression),\nobsessive-compulsive disorder, and smoking addiction. The Company is dedicated\nto leading through superior science and building on its unparalleled body of\nclinical evidence. Additional clinical trials of Deep TMS in various\npsychiatric, neurological, and addiction disorders are underway. Founded in\n2003, with operations in the United States and Israel, BrainsWay is committed\nto increasing global awareness of and broad access to Deep TMS. For the latest\nnews and information about BrainsWay, please visit www.brainsway.com.\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995. Such\nstatements may be preceded by the words “intends,” “may,” “will,”\n“plans,” “expects,” “anticipates,” “projects,” “predicts,”\n“estimates,” “aims,” “believes,” “hopes,” “potential” or\nsimilar words, and also includes any financial guidance and projections\ncontained herein. These forward-looking statements and their implications are\nbased on the current expectations of the management of the Company only and\nare subject to a number of factors and uncertainties that could cause actual\nresults to differ materially from those described in the forward-looking\nstatements. In addition, historical results or conclusions from scientific\nresearch and clinical studies do not guarantee that future results would\nsuggest similar conclusions or that historical results referred to herein\nwould be interpreted similarly in light of additional research or otherwise.\nThe following factors, among others, could cause actual results to differ\nmaterially from those described in the forward-looking statements: risks\nrelating to the Company’s ability to consummate, finance and close proposed\nor potential investments, inadequacy of financial resources to meet future\ncapital requirements; changes in technology and market requirements; delays or\nobstacles in launching and/or successfully completing planned studies and\nclinical trials; failure to obtain approvals by regulatory agencies on the\nCompany’s anticipated timeframe, or at all; inability to retain or attract\nkey employees whose knowledge is essential to the development of Deep TMS\nproducts; unforeseen difficulties with Deep TMS products and processes, and/or\ninability to develop necessary enhancements; unexpected costs related to Deep\nTMS products; failure to obtain and maintain adequate protection of the\nCompany’s intellectual property, including intellectual property licensed to\nthe Company; the potential for product liability; changes in legislation and\napplicable rules and regulations; unfavorable market perception and acceptance\nof Deep TMS technology; inadequate or delays in reimbursement from third-party\npayers, including insurance companies and Medicare; inability to commercialize\nDeep TMS, including internationally, by the Company or through third-party\ndistributors; product development by competitors; inability to timely develop\nand introduce new technologies, products and applications, which could cause\nthe actual results or performance of the Company to differ materially from\nthose contemplated in such forward-looking statements.\n\nAny forward-looking statement in this press release speaks only as of the date\nof this press release. The Company undertakes no obligation to publicly update\nor review any forward-looking statement, whether as a result of new\ninformation, future developments or otherwise, except as may be required by\nany applicable securities laws. More detailed information about the risks and\nuncertainties affecting the Company is contained under the heading “Risk\nFactors” in the Company’s filings with the U.S. Securities and Exchange\nCommission.\n\nContacts: \nBrainsWay:\nIdo Marom\nChief Financial Officer\nIdo.Marom@BrainsWay.com\n\nInvestors:\nBrian Ritchie\nLifeSci Advisors LLC\nbritchie@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ea01c8f7-39be-46d2-a8e0-bc05994f170e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T11:30:00.92703124Z","server_sent_at_ms":1791891000927},"received_at":"2026-10-13T11:30:00.978Z","source_url":null},"analysis":{"id":"155666","press_release_id":"167360","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"BrainsWay announced expanded U.S. insurance coverage for its SWIFT Accelerated Deep TMS protocol, with more than 70 million covered lives now having access under favorable medical policies.\n\nCEO Hadar Levy attributed the momentum to a growing clinical evidence base supporting Deep TMS for major depressive disorder and obsessive-compulsive disorder.\n\nReimbursement expansion is a key commercial driver for TMS adoption, but the release contains no financial figures or quantified revenue impact.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Payer coverage for accelerated Deep TMS crosses 70M covered lives -- a reimbursement tailwind ahead of expected revenue traction."},"keyFigures":{"customDimensions":{"covered_lives_us":"over 70 million"}},"quotedText":"This announcement highlights the increasing pathways toward SWIFT adoption","namedEntities":{"people":[{"name":"Hadar Levy","role":"CEO"},{"name":"Ido Marom","role":"CFO"},{"name":"Brian Ritchie","role":"investor relations contact, LifeSci Advisors"}],"products":["SWIFT Accelerated Deep TMS","Deep TMS","H-coil"],"companies":[{"name":"BrainsWay Ltd.","ticker":"BWAY"},{"name":"LifeSci Advisors LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Positive but incremental commercial update: payer coverage for the SWIFT Accelerated Deep TMS protocol expanded past 70 million covered lives. No revenue, guidance, or financial figures disclosed."},"tickerRelevance":{"others":[],"primary":"BWAY"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":["regulatory"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"incremental coverage expansion, no financials","commercialRelevance":"moderate -- reimbursement is key revenue driver"}},"event_type":"operations_update","event_type_secondary":["regulatory"],"sentiment":"bullish","material_impact_score":2,"narrative":"BrainsWay announced expanded U.S. insurance coverage for its SWIFT Accelerated Deep TMS protocol, with more than 70 million covered lives now having access under favorable medical policies.\n\nCEO Hadar Levy attributed the momentum to a growing clinical evidence base supporting Deep TMS for major depressive disorder and obsessive-compulsive disorder.\n\nReimbursement expansion is a key commercial driver for TMS adoption, but the release contains no financial figures or quantified revenue impact.","key_figures":{"customDimensions":{"covered_lives_us":"over 70 million"}},"named_entities":{"people":[{"name":"Hadar Levy","role":"CEO"},{"name":"Ido Marom","role":"CFO"},{"name":"Brian Ritchie","role":"investor relations contact, LifeSci Advisors"}],"products":["SWIFT Accelerated Deep TMS","Deep TMS","H-coil"],"companies":[{"name":"BrainsWay Ltd.","ticker":"BWAY"},{"name":"LifeSci Advisors LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:30:18.258Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap","eventGravity":"incremental coverage expansion, no financials","commercialRelevance":"moderate -- reimbursement is key revenue driver"}},"durationMs":7627,"modelName":"glm-5.3-flashx"}}